Semaglutide for weight loss.

Semaglutide is a once-weekly injectable GLP-1 receptor agonist sold under the brand names Wegovy (FDA-approved for chronic weight management) and Ozempic (FDA-approved for type 2 diabetes and prescribed off-label for weight loss). It mimics a natural gut hormone that reduces appetite and slows stomach emptying, helping you eat less and feel full longer.

In the STEP trials, adults without diabetes lost on average about 15% of their body weight over 68 weeks on semaglutide 2.4 mg, combined with lifestyle changes. Results vary by individual, dose, and adherence, some lose more, some less. Dr. Eduardo will set realistic expectations for you. Source: NEJM STEP 1 (Wilding et al., 2021)

Adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure, high cholesterol, prediabetes, or sleep apnea, may be candidates. A medical evaluation is required first. Semaglutide is not for people with a personal or family history of medullary thyroid cancer or MEN2, and is not used in pregnancy.

The most common side effects are gastrointestinal (nausea, diarrhea, vomiting, constipation, and reflux) and are usually mildest at the lowest dose, easing as your body adjusts. Starting low and titrating slowly, eating smaller protein-forward meals, and staying hydrated help. Rare but serious risks include pancreatitis and gallbladder problems; we review your full risk profile before you start.

Semaglutide for weight loss is a once-weekly subcutaneous injection you give yourself with a prefilled pen, on the same day each week. The dose is titrated upward over several months to the level you tolerate best. Dr. Eduardo personalizes your titration schedule and adjusts it at follow-up visits.

No. Omnia Health prescribes only FDA-approved, branded semaglutide (Wegovy, Ozempic). We do not offer compounded semaglutide. Compounded versions are not FDA-evaluated for safety, quality, or effectiveness, and we believe branded, regulated medicine is the right standard for our patients.

Yes and no. Both contain the exact same active ingredient, semaglutide, made by the same manufacturer. The difference is what the FDA approved each one for and at what dose. Wegovy is approved for chronic weight management; Ozempic is approved for type 2 diabetes. Wegovy also comes in a higher maximum dose. Think of them as the same molecule in two differently labeled boxes.

For weight loss specifically, Wegovy is the medication designed and FDA-approved for the job, and it goes to a higher dose (2.4 mg weekly, with a 7.2 mg Wegovy HD strength approved in 2026). In the STEP 1 trial, adults on semaglutide 2.4 mg lost about 15% of body weight over 68 weeks. Ozempic uses the same molecule but tops out at 2.0 mg and is studied and approved for diabetes, so any weight loss on it is off-label. When appropriate, Dr. Eduardo prescribes the branded medication that fits your diagnosis and coverage. Source: STEP 1 (Wilding et al., NEJM 2021).

Ozempic is FDA-approved for type 2 diabetes, not weight loss, so prescribing it purely for weight is off-label and insurers generally will not cover it for that purpose. If your goal is weight management, Wegovy (the same molecule, approved for that use) is usually the appropriate branded choice. Our team verifies your specific benefits and explains the options during your evaluation.

Wegovy HD is a higher-dose 7.2 mg strength of semaglutide that the FDA approved in March 2026 for chronic weight management, above the previous 2.4 mg maximum. Whether a higher dose is right for you is an individual medical decision based on your response, tolerance and goals, made with your physician.

Yes. The FDA approved Wegovy tablets, oral semaglutide 25 mg, on December 22, 2025 for chronic weight management and for cardiovascular risk reduction in adults with overweight or obesity and established cardiovascular disease. It is the same molecule as the injection. In the OASIS 4 trial it averaged about 13.6% body-weight loss over 64 weeks. It must be taken on an empty stomach with no more than four ounces of water, then nothing else for 30 minutes. It is not the same as Rybelsus (oral semaglutide 7 or 14 mg, approved for diabetes).

It depends on which routine you will actually keep. The Wegovy injection is once weekly with no food restrictions and a longer track record. The tablet is once daily and demands a protected empty-stomach window every morning. Patients who dislike needles often do better on the pill; patients with chaotic mornings do better on the injection. Dr. Eduardo will make a recommendation rather than leaving the choice to a brochure.